GSK Steps Up Parkinson’s Focus With US Biotech Deal
2 days ago · Listen. 1:49. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s …
GSK pays Flagship biotech $80M for preclinical neuro pact
2 days ago · GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks. GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius …
GSK partners with Flagship startup to hunt for Parkinson’s drugs
2 days ago · The deal with GSK represents an upturn in fortune for Vesalius, which laid off 40% of its workforce in September 2022. Launched in 2019, the startup was co-founded by …
Vesalius Announces Multi-Target Strategic Alliance with GSK to …
2 days ago · "GSK brings numerous strengths to this alliance including its global scale and expertise in human genetics," said Amanda Kay, Ph.D., Senior Partner and Chief Business …
Health Canada approves GSK’s Ojjaara for ... - Yahoo Finance
1 day ago · GSK. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The …
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies …
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in …
GSK (GSK) Q3 Earnings Surpass Estimates - Yahoo Finance
Oct 30, 2024 · GSK. GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share …
GSK makes a strong start to 2024 with improving outlook for the …
May 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% …
GSK delivers strong 2023 performance and upgrades growth …
Jan 31, 2024 · Broad-based performance drives sales, profits and earnings growth: Total 2023 sales £30.3 billion +5% and +14% ex COVID. Vaccines sales +25%, +24% ex COVID. …